Schmidt, Axel Jeremias; Rasi, Manuela; Esson, Cate; Christinet, Vanessa; Ritzler, Michael; Lung, Thomas; Hauser, Christoph V; Stöckle, Marcel; Jouinot, Florent; Lehner, Andreas; +3 more... Lange, Katharina; Konrad, Torsten; Vernazza, Pietro L; (2020) The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men. Swiss medical weekly, 150 (5153). w20392-. ISSN 1424-7860 DOI: https://doi.org/10.4414/smw.2020.20392
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
OBJECTIVES: In Switzerland, universal health insurance does not cover any routine testing for sexually transmitted infections (STIs), not even in individuals at high risk, and extra-genital swabbing is not standard of care. We determined the prevalence and incidence of human immunodeficiency virus (HIV), viral hepatitis and non-viral STIs in a multicentre prospective observational cohort of multi-partner men who have sex with men (MSM) and other men. MATERIALS AND METHODS: Between January 2016 and June 2017, we offered free STI testing to all men with multiple sexual partners (three or more in the previous 12 months), with follow-up examinations every 6 months. We used multiplex polymerase chain-reaction testing (for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium) on pooled swabs (pharynx, urethra/vagina, anus), and antibody tests for HIV and Treponema pallidum at every visit, and for hepatitis B/C at baseline. RESULTS: We screened 779 multi-partner MSM and 92 other men. Previously undiagnosed HIV was found in 0.5% vs 0.0%, respectively and T. pallidum antibodies in 15.3% vs 1.1%. STIs requiring antibiotic treatment comprised: active syphilis 1.7% vs 0.0%; N. gonorrhoeae 10.3% vs 0.0%; C. trachomatis 8.7% vs 1.1%. One in four MSM versus 1 in 100 other multi-partner men had any of these three STIs at baseline. 10.4% vs 1.3% had a history of hepatitis B, 31.9% vs 47.3% had no immunity (HBs-AB <10 IU/l). Ten MSM had HCV antibodies (1.4%), with 8 out of the 10 being MSM with HIV; HCV seroprevalence was 0.3% among HIV-negative MSM. In MSM, incidence of the three bacterial STIs was 25.5 per year over 333 person years of follow-up, HIV incidence was 0.3%. Non-condom-use (in the last 3 months) for anal/vaginal sex was not associated with STIs. Independent risk factors were sex with men (adjusted odds ratio [aOR] 16.4) and the number of sexual partners (aOR 2.3 for >20). CONCLUSION: Among MSM, but not among other multi-partner men, STIs, mostly asymptomatic, are common. Given the high risk of onward transmission, low-cost or free routine screening of multi-partner MSM is a public health priority.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Public Health and Policy > Public Health, Environments and Society |
PubMed ID | 33382077 |
Elements ID | 156288 |
Downloads
Restricted to: Repository staff only
Filename: SchmidtAJ_VernazzaP_2020_smw_20392_STAR-trial_men.pdf
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Filename: Vernazza_etal_2020-The-Swiss-STAR-trial-appendix.pdf.pdf
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Download